Nightfood Signs LOI to Acquire Hilton Garden Inn in Rancho Mirage, California, Adjacent to Disney's Cotino Development
Strategic acquisition strengthens NGTF's real estate footprint and positions the Company for institutional-grade hospitality automation deployment
TARRYTOWN, N.Y., May 12, 2025 (GLOBE NEWSWIRE) -- via IBN – Nightfood Holdings, Inc. (OTCQB: NGTF) ('Nightfood' and the 'Company'), a hospitality automation company pioneering artificial intelligence (AI)-powered robotics and strategic hotel ownership, today announces the execution of a Letter of Intent (LOI) to acquire the Hilton Garden Inn located in Rancho Mirage, California. This 120-room property, with plans for a five room expansion to 125 rooms, is strategically located adjacent to Cotino™, a Storyliving by Disney community—a first-of-its-kind, 618-acre residential resort development.
The total transaction is valued at $36.93 million, making it one of the largest acquisitions in the Company's history to date. The Hilton Garden Inn will continue to operate under the Hilton flag and serve as a flagship property for Nightfood's expanding Robotics-as-a-Service (RaaS) platform—designed to reduce labor costs, address staffing challenges, and enhance operational efficiency across the hospitality industry.
This acquisition is expected to be the second of many as Nightfood actively pursues similar high-value assets, including some at even higher price points. The Company's strategic focus remains on acquiring real estate that complements its automation platform, driving long-term growth and shareholder value.
'This acquisition reflects our commitment to building a high-impact, asset-backed platform that merges real estate and automation,' said Jimmy Chan, CEO of Nightfood Holdings. 'The proximity to Disney's Cotino project offers significant long-term upside, and this Hilton property gives us a high-visibility location to showcase our robotic automation technologies in a live, revenue-generating environment.'
Strategic Location and Long-Term Value
The Hilton Garden Inn is positioned to benefit from Cotino's transformative impact, which is expected to attract significant year-round foot traffic, affluent residents, and both domestic and international visitors. Nightfood anticipates long-term gains in both occupancy rates and average daily rates (ADR), driven by the Cotino effect and the operational cost savings delivered by its automation suite.
Key Transaction Terms
Purchase Price: $36.93 million (including planned expansion to 125 rooms).
Equity Consideration: Net $26.43 million in Series C Convertible Preferred Stock (tax-free share exchange, Section 368).
Earn-Out: Additional of $3 million Series C shares upon completion of five new guest rooms.
Exclusivity: 180-day No-Shop period.
Closing Conditions:
Delivery of two years of audited financials.
Nightfood's uplisting to NASDAQ or NYSE American.
Satisfaction of outstanding mortgage (not to exceed $10.5 million).
Flagship Location for Automation Showcase
Nightfood plans to leverage the Hilton Garden Inn as its second live testing ground for its AI-powered Robotics-as-a-Service (RaaS) platform, following the successful deployment at its first test property, a Holiday Inn. By operating under a different flagship brand, Nightfood can refine and expand its automation solutions across diverse hospitality environments. This aligns with the Company's broader strategy of combining advanced automation with prime real estate assets, further establishing its leadership in technology-driven hospitality solutions.
Looking Ahead
As part of its disciplined growth strategy, Nightfood will continue pursuing strategic acquisitions and expanding its automation capabilities. Investors can expect further updates as the Company advances through closing steps and uplisting preparations.
About Nightfood Holdings, Inc. (OTCQB: NGTF)
Nightfood Holdings, Inc. is revolutionizing the hospitality industry by combining AI-powered robotics with strategic hotel acquisitions. The Company's innovative approach uses advanced automation technology to significantly improve hotel efficiency, reduce operating costs, and address labor challenges. As automation rapidly becomes the standard rather than a trend in hospitality, Nightfood is committed to setting that standard — delivering intelligent solutions that enhance guest experiences and streamline operations.
With its dual focus on owning hotel properties and offering Robotics-as-a-Service (RaaS), NGTF is strategically positioned to capitalize on the rapidly growing global service robotics market, which is expected to surpass $170 billion by 2030. This integrated business model provides scalable revenue streams and positions NGTF as a leader in technology-driven hospitality solutions.
Forward-Looking Statements
This press release contains forward-looking statements regarding future events and Nightfood Holdings' expected performance. These statements are subject to risks and uncertainties, and actual results may differ materially from expectations. Investors are encouraged to review the Company's SEC filings for additional information.
For more information on Nightfood Holdings, Inc. (OTCQB: NGTF), please visit www.nightfoodholdings.com.
Investor & Media Contacts
Investor Relations Contact: Nightfood Holdings, Inc. Email: ir@nightfoodholdings.com
Media Relations Contact: Email: media@nightfoodholdings.com Phone: (866) 261-7778
Corporate Communications
IBN Austin, Texas www.InvestorBrandNetwork.com 512.354.7000 Office Editor@InvestorBrandNetwork.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Helius Medical Technologies, Inc. Compliant with Nasdaq Bid Price Rule Listing Criteria
Company previously granted extension until June 30, 2025 to regain compliance with Nasdaq's Equity Rule requirement NEWTOWN, Pa., June 04, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) ('Helius' or the 'Company'), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that on June 3, 2025, Helius received formal notice from the Nasdaq Hearings Panel of The Nasdaq Stock Market LLC (the 'Panel') indicating that Helius has evidenced full compliance with the minimum bid price requirement set forth Listing Rules 5550(a)(2) (the 'Bid Price Rule'). The Panel further reminded the Company that it is also required to regain compliance with the equity requirement in Listing Rule 5550(b)(1) (the 'Equity Rule') by June 30, 2025 under the extension previously granted by the Panel. Accordingly, the Nasdaq Listing Qualifications hearing process will remain open until the Company has demonstrated compliance with all of The Nasdaq Stock Market's continued listing requirements. About Helius Medical Technologies, Inc. Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology platform that amplifies the brain's ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company's first commercial product is the Portable Neuromodulation Stimulator (PoNS®). For more information about PoNS or Helius Medical Technologies, visit Cautionary Disclaimer Statement Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as 'believe,' 'expect,' 'continue,' 'will,' 'goal,' 'aim' and similar expressions. Such forward-looking statements include, among others, but are not limited to, statements regarding the Company's ability to achieve and maintain compliance with the Nasdaq listing rules. The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law. Investor Relations Contact Philip Trip TaylorGilmartin Groupinvestorrelations@
Yahoo
32 minutes ago
- Yahoo
Avant Technologies and Partner, Ainnova, Finalizing Automated Retinal Camera Prototype Ahead of Full-Scale Development
LAS VEGAS, June 4, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the Company is in the final stages of prototyping its proprietary automated retinal camera. Ainnova's new device will offer users a low cost, easier to use camera that captures images automatically and then uploads those images to the Company's Vision AI software platform, which then produces a "risk report" in mere seconds. Vinicio Vargas, Chief Executive Officer at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp., said, "The cost of a fundus camera has always been a barrier to entry into in this market, so our low-cost camera, which is a fraction of the cost of currently available cameras on the market, should allow us to not only enter the market, but to capture a large share of the market. "Another significant advantage will be that our camera will be seamlessly packaged together with our Vision AI platform, allowing us to refer more patients in less time and accurately to medical specialists. Also, one of our objectives is to integrate other technologies to this preventive screening, expanding the scope from only diabetic patients to patients who have other risk factors and want to prevent other diseases from a more complete approach." Vision AI is a powerful cutting-edge, AI-driven platform that can quickly and accurately detect the early markers of a host of diseases by applying AI models to examine imaging data from the eye to expedite earlier detection and allow patients to better manage their disease. The diseases that Vision AI can detect, include diabetic retinopathy, other retinopathies, such as glaucoma, macular edema, age-related macular degeneration, and other anomalies, as well as other diseases that do not require retinal images, and instead, use other datapoints that Ainnova has integrated into the software like the detection of cardiovascular disease (CVD), type 2 diabetes, liver fibrosis, and chronic kidney disease (CKD). Currently, Ainnova's Vision AI software works well with any fundus camera on the market; however, Ainnova and Avant are aiming for exclusivity by developing a lower-cost, easier to use camera. Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova, will develop the retinal cameras as part of the joint venture and licensing deal to facilitate the development of Ainnova's technology portfolio. AAC owns the global licensing rights to develop, maintain, and market Ainnova's technology portfolio. About Ainnova Tech, Inc. Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions. About Avant Technologies, Inc. Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology. More information about Avant can be found at You can also follow us on social media at: Forward-Looking Statements Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release. Contact:Avant Technologies, Inc. info@ View original content to download multimedia: SOURCE Avant Technologies Inc.
Yahoo
33 minutes ago
- Yahoo
Sharps Technology Begins Shipments Across Three Customer Orders Under Previously Announced Purchase Agreements
Shipments include initial deliveries of SecureGard™ and SoloGard™ smart safety syringes from its Hungary-based manufacturing facility Deliveries mark the Company's transition to a commercial-stage, revenue-generating company NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (Nasdaq: 'STSS' and 'STSSW') ('Sharps'), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry, today announced the initiation of shipments for previously announced purchase orders across three customer orders. These shipments mark the Company's first deliveries of its SecureGard™ and SoloGard™ product lines and its transition to generating commercial revenue. Sharps has initiated shipment of its first commercial order of Sologard under a previously announced $50 million supply agreement with a U.S.-based leader in IV flushing solutions. The delivery includes customized 10mL SoloGard smart safety syringes manufactured at the Company's upgraded facility in Hungary. SoloGard is a specialized, FDA- and WHO-approved smart safety syringe featuring ultra-low waste design, standard luer lock compatibility, and re-use prevention technology. This inaugural $400,000 purchase order marks the beginning of a five-year contract to supply up to 500 million syringes and represents the first revenue-generating shipment under the strategic supply agreement. The manufacturing of SoloGard is supported by advanced molding and automation technologies recently invested in by the Company, enabling Sharps to meet the anticipated increase in demand under the agreement during the second half of 2025. In a separate shipment, Sharps delivered SecureGard smart safety syringes to a Hungarian vaccine provider following a $100,000 purchase order. SecureGard is an FDA- and WHO-approved, CE Mark-certified specialized safety syringe featuring an integrated active recessed safety system, ultra-low waste design, and re-use prevention technology. This marks the customer's first commercial order and reflects growing global demand for Sharps' safety syringe technologies. Combined with the SoloGard order, total purchase commitments reached approximately $500,000, establishing Sharps as a revenue-producing company and supporting its transition to commercial operations. Additionally, Sharps has commenced shipment of 200,000 units of 1mL low dead space syringes to a Swiss-based global provider of cosmetic, dental, and ophthalmic injectable therapies. The syringes will be used in a specialized injection pen for the delivery of Botox and represent the first tranche of a 1-million-unit order. This shipment underscores Sharps' ability to serve diverse therapeutic markets and meet the technical requirements of premium, differentiated injectable delivery platforms. 'These initial shipments mark a key operational milestone as Sharps officially transitions to a commercial-stage company,' stated Robert Hayes, Chief Executive Officer of Sharps Technology. 'For the first time, we are recognizing product revenue across multiple product lines and global markets. This achievement validates years of R&D, strategic planning, and manufacturing investment. We've made significant upgrades to our Hungary-based facility to support these deliveries, including the installation of next-generation molding and automation technologies, to ensure we can meet near-term demand and scale rapidly to fulfill long-term contracts. These enhancements not only increase our production capacity, but also elevate the consistency and quality required by our customers.' All products are being manufactured and shipped from Sharps' facility in Hungary, which has undergone significant upgrades to support high-volume, high-precision production. The Company continues to build inventory and expand capacity to support current and future purchase commitments under long-term strategic agreements. Mr. Hayes concluded: 'Our progress reflects strong execution by the Sharps team and the strategic value of our manufacturing investments. We look forward to deepening relationships with our partners and driving additional growth in the quarters ahead.' About Sharps Technology:Sharps Technology is an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry. The Company's product lines focus on providing ultra-low waste capabilities, that incorporate syringe technologies that use both passive and active safety features. Sharps also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. The Company has a manufacturing facility in Hungary. For additional information, please visit FORWARD-LOOKING STATEMENTS:This press release contains 'forward-looking statements'. Forward-looking statements reflect our current view about future events. When used in this press release, the words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'future,' 'intend,' 'plan,' 'poised' or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity, and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance, or achievements. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Investor Contact:Holdsworth PartnersAdam HoldsworthPhone: 917-497-9287Email: IR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
